Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

Clear aligner volumes increased 6.1% year-over-year, with strong performance in EMEA, APAC, and Latin America, offset by seasonal softness in North America. Clear aligner ASPs declined, attributed to ...